1. Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000;15:1014–1021PMID : 10862640.
2. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calficications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001;38:938–942PMID : 11641313.
3. Asmar R, Benetos A, Topouchian J, et al. Assesment of arterial distensibility by automatic pulse wave velocity measurement: validation and clinical application studies. Hypertension 1995;26:485–490PMID : 7649586.
4. Lacey DL, Dunstan CR, Kelley M, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309–319PMID : 9108485.
5. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165–176PMID : 9568710.
6. Westenfeld R, Jahnen-Dechent W, Ketteler M. Vascular calcification and fetuin-A deficiency in chronic kidney disease. Trends Cardiovasc Med 2007;17:124–128PMID : 17482094.
7. Nishiura R, Fujimoto S, Sato Y, et al. Elevated osteoprotegerin levels predict cardiovascualr events in new hemodialysis patients. Am J Nephrol 2009;29:257–263PMID : 18802328.
8. Sigrist MK, Levin A, Er L, McIntyre CW. Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification. Nephrol Dial Transplant 2009;24:3157–3162PMID : 19491380.
9. Nakashima A, Carrero JJ, Qureshi AR, et al. Plasma osteoprotegerin, arterial stiffness, and mortality in normoalbuminemic Japanese hemodialysis patients. Osteoporos Int 2011;22:1695–1701PMID : 20812007.
10. Speer G, Fekete BC, El Hadj Othmane T, et al. Serum osteoprotegerin level, carotid-femoral pulse wave velocity and cardiovascular survival in haemodialysis patients. Nephrol Dial Transplant 2008;23:3256–3262PMID : 18450827.
11. Hermans MM, Brandenburg V, Ketteler M, et al. Study on the relationship of serum fetuin-A concentration with aortic stiffness in patients on dialysis. Nephrol Dial Transplant 2006;21:1293–1299PMID : 16396973.
13. Ketteler M, Bongartz P, Westenfeld R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003;361:827–833PMID : 12642050.
14. Swedberg K, Cleland J, Dargie H, et al. Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology: guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur Heart J 2005;26:1115–1140PMID : 15901669.
15. O'Rourke MF, Staessen JA, Vlachopoulos C, Duprez D, Plante GE. Clinical application of arterial stiffness: definitions and reference values. Am J Hypertens 2002;15:426–444PMID : 12022246.
16. Park S, Kim JB, Shim CY, et al. The influence of serum aldosterone and the aldosterone-renin ratio on pulse wave velocity in hypertensive patients. J Hypertens 2007;25:1279–1283PMID : 17563542.
17. Kuzniar J, Porazko T, Klinger M. Relationship between fetuin-A concentration, elevated levels of inflammatory markers, and arterial wall stiffness in end stage kidney disease. J Ren Nutr 2008;18:83–86PMID : 18089450.
18. Nitta K, Akiba T, Uchida K, et al. The progression of vascular calcification and serum osteoprogerin levels in patients on long-term hemodialysis. Am J Kidney Dis 2003;42:303–309PMID : 12900812.
19. Barreto DV, Barreto FC, Carvalho AB, et al. Coronary calcification in hemodialysis patients: the contribution of traditional and uremia-related risk factors. Kidney Int 2005;67:1576–1582PMID : 15780114.
20. London GM, Guerin AP, Verbeke FH, et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007;18:613–620PMID : 17202417.
22. Stenvinkel P, Wang K, Qureshi AR, et al. Low fetuin-A levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin. Kidney Int 2005;67:2383–2392PMID : 15882283.
23. Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997;386:78–81PMID : 9052783.
24. Schinke T, Amendt C, Trindl A, Poschke O, Muller-Esterl W, Jahnen-Dechent W. The serum protein alpha 2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells: a possible role in mineralization and calcium homeostasis. J Biol Chem 1996;271:20789–20796PMID : 8702833.
25. Metry G, Stenvinkel P, Qureshi AR, et al. Low serum fetuin-A concentration predicts poor outcome only in the presence of inflammation in prevalent haemodialysis patients. Eur J Clin Invest 2008;38:804–811PMID : 19021697.
26. Honda H, Qureshi AR, Heimburger O, et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006;47:139–148PMID : 16377395.
27. Chen HY, Chiu YL, Hsu SP, et al. Association of serum fetuin A with truncal obesity and dyslipidemia in non-diabetic hemodialysis patients. Eur J Endocrinol 2009;160:777–783PMID : 19228823.
29. Raggi P, Bellasi A, Ferramosca E, Islam T, Muntner P, Block GA. Association of pulse wave velocity with vascular and valvular calcification in hemodialysis patients. Kidney Int 2007;71:802–807PMID : 17311068.
30. Haydar AA, Covic A, Colhoun H, Rubens M, Goldsmith DJ. Coronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients. Kidney Int 2004;65:1790–1794PMID : 15086918.
31. Hjelmesaeth J, Ueland T, Flyvbjerg A, et al. Early posttransplant serum osteoprotegerin levels predict long-term (8-year) patient survival and cardiovascular death in renal transplant patients. J Am Soc Nephrol 2006;17:1746–1754PMID : 16687626.
32. Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004;109:2175–2180PMID : 15117849.
33. Morena M, Terrier N, Jaussent I, et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol 2006;17:262–270PMID : 16280472.